Treatment of inflammatory disease
CA 2344590 C · Owner: Panayi, Gabriel Stavros · Inventors: Panayi, Gabriel Stavros; Bodman-Smith, Mark Duncan; Lanchbury, Jeremy Shaun
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The immunoglobulin heavy chain binding protein BiP (78KD) or a peptide , derived therefrom provides a reagent for indicating the presence of rheumatoid arthritis. The protein used is recombinant BiP(78KD) having a defined sequence. A prognostic or diagnostic test for RA may be an ELISA assay or a Western Blot. The invention also includes a method of testing for RA using a , protein BiP(78KD) or a cDNA sequence coding therefor to determine the presence of antibodies to said protein. The invention also includes a method of therapeutic treatment of RA comprising administering the protein BiP(78KD) or a DNA coding therefor e.g. by the intravenous nasal, oral, or cutaneous route.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 8, 1999 and granted May 10, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 8, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 8, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.